<?xml version='1.0' encoding='utf-8'?>
<document id="25161155"><sentence text="Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers."><entity charOffset="20-33" id="DDI-PubMed.25161155.s1.e0" text="empagliflozin" /><entity charOffset="37-51" id="DDI-PubMed.25161155.s1.e1" text="sodium glucose" /><entity charOffset="83-94" id="DDI-PubMed.25161155.s1.e2" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.25161155.s1.e0" e2="DDI-PubMed.25161155.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25161155.s1.e0" e2="DDI-PubMed.25161155.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25161155.s1.e0" e2="DDI-PubMed.25161155.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25161155.s1.e1" e2="DDI-PubMed.25161155.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25161155.s1.e1" e2="DDI-PubMed.25161155.s1.e2" /></sentence><sentence text="This study was undertaken to investigate potential drugdrug interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and simvastatin"><entity charOffset="85-99" id="DDI-PubMed.25161155.s2.e0" text="sodium glucose" /><entity charOffset="126-139" id="DDI-PubMed.25161155.s2.e1" text="empagliflozin" /><entity charOffset="144-155" id="DDI-PubMed.25161155.s2.e2" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.25161155.s2.e0" e2="DDI-PubMed.25161155.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25161155.s2.e0" e2="DDI-PubMed.25161155.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25161155.s2.e0" e2="DDI-PubMed.25161155.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25161155.s2.e1" e2="DDI-PubMed.25161155.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25161155.s2.e1" e2="DDI-PubMed.25161155.s2.e2" /></sentence><sentence text="" /><sentence text="In this open-label, randomized crossover trial, healthy volunteers (median (range) age 36" /><sentence text="5 (20 - 50) years) received 3 single-dose treatments: 25 mg empagliflozin (n = 18), 40 mg simvastatin (n = 17), and 25 mg empagliflozin with 40 mg simvastatin (n = 18)"><entity charOffset="60-73" id="DDI-PubMed.25161155.s5.e0" text="empagliflozin" /><entity charOffset="90-101" id="DDI-PubMed.25161155.s5.e1" text="simvastatin" /><entity charOffset="122-135" id="DDI-PubMed.25161155.s5.e2" text="empagliflozin" /><entity charOffset="147-158" id="DDI-PubMed.25161155.s5.e3" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.25161155.s5.e0" e2="DDI-PubMed.25161155.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25161155.s5.e0" e2="DDI-PubMed.25161155.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25161155.s5.e0" e2="DDI-PubMed.25161155.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25161155.s5.e0" e2="DDI-PubMed.25161155.s5.e3" /><pair ddi="false" e1="DDI-PubMed.25161155.s5.e1" e2="DDI-PubMed.25161155.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25161155.s5.e1" e2="DDI-PubMed.25161155.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25161155.s5.e1" e2="DDI-PubMed.25161155.s5.e3" /><pair ddi="false" e1="DDI-PubMed.25161155.s5.e2" e2="DDI-PubMed.25161155.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25161155.s5.e2" e2="DDI-PubMed.25161155.s5.e3" /></sentence><sentence text="" /><sentence text="Based on standard criteria, simvastatin had no effect on empagliflozin area under the plasma concentration-time curve (AUC(0-∞), adjusted geometric mean ratio (GMR): 102"><entity charOffset="28-39" id="DDI-PubMed.25161155.s7.e0" text="simvastatin" /><entity charOffset="57-70" id="DDI-PubMed.25161155.s7.e1" text="empagliflozin" /><pair ddi="false" e1="DDI-PubMed.25161155.s7.e0" e2="DDI-PubMed.25161155.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25161155.s7.e0" e2="DDI-PubMed.25161155.s7.e1" /></sentence><sentence text="05; 90% CI: 98" /><sentence text="90 - 105" /><sentence text="29) or maximum plasma concentration (C(max), GMR: 109" /><sentence text="49; 90% CI: 96" /><sentence text="91 - 123" /><sentence text="69)" /><sentence text=" There were only minor deviations in simvastatin AUC(0-∞) (GMR: 101" /><sentence text="26; 90% CI: 80" /><sentence text="06 - 128" /><sentence text="07) and C(max) (GMR: 97" /><sentence text="18; 90% CI: 76" /><sentence text="30 - 123" /><sentence text="77) when co-administered with empagliflozin"><entity charOffset="30-43" id="DDI-PubMed.25161155.s20.e0" text="empagliflozin" /></sentence><sentence text=" Empagliflozin had no effect on AUC(0-∞) (GMR: 104"><entity charOffset="1-14" id="DDI-PubMed.25161155.s21.e0" text="Empagliflozin" /></sentence><sentence text="87; 90% CI: 90" /><sentence text="09 - 122" /><sentence text="07) or C(max) (GMR: 97" /><sentence text="27; 90% CI: 84" /><sentence text="90 - 111" /><sentence text="44) of simvastatin acid, the active metabolite of simvastatin"><entity charOffset="7-23" id="DDI-PubMed.25161155.s27.e0" text="simvastatin acid" /><entity charOffset="50-61" id="DDI-PubMed.25161155.s27.e1" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.25161155.s27.e0" e2="DDI-PubMed.25161155.s27.e0" /><pair ddi="false" e1="DDI-PubMed.25161155.s27.e0" e2="DDI-PubMed.25161155.s27.e1" /></sentence><sentence text=" Adverse events (AEs) were reported for 6 subjects on empagliflozin, 4 on simvastatin, and 5 on co-administered treatment"><entity charOffset="54-67" id="DDI-PubMed.25161155.s28.e0" text="empagliflozin" /><entity charOffset="74-85" id="DDI-PubMed.25161155.s28.e1" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.25161155.s28.e0" e2="DDI-PubMed.25161155.s28.e0" /><pair ddi="false" e1="DDI-PubMed.25161155.s28.e0" e2="DDI-PubMed.25161155.s28.e1" /></sentence><sentence text=" No serious AEs or investigator-defined drug-related AEs were reported" /><sentence text="" /><sentence text="No relevant drug-drug interaction was observed, and pharmacokinetic results suggest that no dose adjustments for either drug are necessary when empagliflozin and simvastatin are co-administered"><entity charOffset="144-157" id="DDI-PubMed.25161155.s31.e0" text="empagliflozin" /><entity charOffset="162-173" id="DDI-PubMed.25161155.s31.e1" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.25161155.s31.e0" e2="DDI-PubMed.25161155.s31.e0" /><pair ddi="false" e1="DDI-PubMed.25161155.s31.e0" e2="DDI-PubMed.25161155.s31.e1" /></sentence><sentence text=" Empagliflozin was well tolerated when administered alone or in combination with simvastatin"><entity charOffset="1-14" id="DDI-PubMed.25161155.s32.e0" text="Empagliflozin" /><entity charOffset="81-92" id="DDI-PubMed.25161155.s32.e1" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.25161155.s32.e0" e2="DDI-PubMed.25161155.s32.e0" /><pair ddi="false" e1="DDI-PubMed.25161155.s32.e0" e2="DDI-PubMed.25161155.s32.e1" /></sentence><sentence text="" /></document>